New synthetic corticosteroids inhibit Epstein–Barr virus release

[Display omitted] Novel spiroandrostene-17,6'-[1,3,4]thiadiazines obtained by synthesis from 16β,17β-epoxy-17-isopregn-5-en-3β-ol-20-one and N-aryl-2-hydrazino-2-thioxoacetamide efficiently inhibited the release of Epstein–Barr virus from cells carrying the virus in culture. Other studied stero...

Full description

Saved in:
Bibliographic Details
Published inMendeleev communications Vol. 31; no. 5; pp. 667 - 669
Main Authors Malykh, Andrei G., Pavlov, Andrey R., Komkov, Alexander V., Volkova, Yulia A., Menchikov, Leonid G., Zavarzin, Igor V.
Format Journal Article
LanguageEnglish
Published Elsevier B.V 01.09.2021
Subjects
1,3,4-thiadiazine
androstene
antiviral activity
Epstein–Barr virus
spironolactone
steroids
1,3,4-thiadiazine
steroids
androstene
antiviral activity
spironolactone
Epstein–Barr virus
Online AccessGet full text

Cover

More Information
Summary:[Display omitted] Novel spiroandrostene-17,6'-[1,3,4]thiadiazines obtained by synthesis from 16β,17β-epoxy-17-isopregn-5-en-3β-ol-20-one and N-aryl-2-hydrazino-2-thioxoacetamide efficiently inhibited the release of Epstein–Barr virus from cells carrying the virus in culture. Other studied steroids, such as Spirolactone, Digitonin, Diosgenin, and Hecogenin were inactive. DMSO alone was found to inhibit the virus release, as well, likely, because of changing properties of the cell membranes. The novel steroids, Spironolactone and most analogues display no or low cell toxicity while Digitonin produced a significant toxic effect.
ISSN:0959-9436
DOI:10.1016/j.mencom.2021.09.025